Paclitaxel Noninferior to Paclitaxel: Registry‐Scale Evidence for an Urea‐Excipient Drug‐Coated Balloon in a Real World Population: A Commentary on the SCAAR Nationwide Comparative Registry Analysis

Using SCAAR (Swedish Coronary Angiography and Angioplasty Registry), a nationwide database with virtually complete follow-up, the investigators analyzed 6488 DCB procedures (8054 devices) from August 2021 to May 2024.The study was framed as a target trial emulation, 4,5 with prespecified eligibility, treatment strategies, and outcome definitions, and addressed confounding through propensity score-weighted Cox regression adjusting for a prespecified set of clinical, angiographic, and procedural variables.One feature of the design is critical.The primary comparison, ureaexcipient PCBs (Prevail, Medtronic; 1797 procedures) versus other contemporary DCBs (4691 procedures), is essentially paclitaxel versus predominantly paclitaxel